Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (431-440 of 441) with videos related to

Pageof 45
Sort By:
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
NEJM Evidence|October 22, 2024
Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver DiseaseWenyi Gu, Victor de Lédinghen, Christophe Aubé, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
Gut|March 20, 2021
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysisVictor Sapena, Marco Enea, Ferran Torres, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
Gut|January 22, 2021
Two-dimensional shear wave elastography predicts survival in advanced chronic liver diseaseJonel Trebicka, Wenyi Gu, Victor de Ledinghen, et al.
Journal of Hepatology|January 10, 2025
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosisElisabetta Degasperi, Maria Paola Anolli, Mathias Jachs, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 13, 2022
ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohortsIsabelle Ollivier-Hourmand, Yohann Repesse, Pierre Nahon, et al.
Pageof 45

Showing results (431-440 of 441) with videos related to

Sort By:
Pageof 45
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
NEJM Evidence|October 22, 2024
Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver DiseaseWenyi Gu, Victor de Lédinghen, Christophe Aubé, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
Gut|March 20, 2021
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysisVictor Sapena, Marco Enea, Ferran Torres, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
Gut|January 22, 2021
Two-dimensional shear wave elastography predicts survival in advanced chronic liver diseaseJonel Trebicka, Wenyi Gu, Victor de Ledinghen, et al.
Journal of Hepatology|January 10, 2025
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosisElisabetta Degasperi, Maria Paola Anolli, Mathias Jachs, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 13, 2022
ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohortsIsabelle Ollivier-Hourmand, Yohann Repesse, Pierre Nahon, et al.
Pageof 45